GLPwatch

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy

NCT07728669 · Recruiting

Last updated 2026-08-27

This clinical trial is testing a digital dietary intervention in adults with type 2 diabetes, obesity, or metabolic syndrome who are receiving GLP-1 receptor agonist therapy to see how it affects their blood sugar levels over 12 weeks.

Status Recruiting Currently enrolling participants.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) study
Participants 120 people Planned (estimated).
Who can join Ages 21–65 · all sexes
Timeline Started 2026-07 · est. completion 2027-01
Where 1 site · Kazakhstan

What this study is testing ClinicalTrials.gov NCT07728669 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study. The main question is: Does the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone? The study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety. Researchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support. Participants in both groups will: * Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol. * Photograph everything they eat and drink. * Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study. * Be able to view the results of the food photograph analysis. The photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.

Treatments tested

Main thing measuredChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
SponsorKazakh Academy of Nutrition
Conditions studiedType 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07728669 ↗